Regimen-related Mortality Risk in Patients Undergoing Peritoneal Dialysis Using Hypertonic Glucose Solution: A Retrospective Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The main purpose of this study was to quantify the risk of mortality linked to various regimens of hypertonic peritoneal dialysis (PD) solution. Methods: A retrospective cohort study of patients using home-based PD was carried out. The prescribed regimen of glucose-based PD solution for all patients, determined on the basis of their individual conditions, was extracted from their medical chart records. The primary outcome was death. The treatment regimens were categorized into 3 groups according to the type of PD solution used: original PD (1.5% glucose), shuffle PD (1.5 and 2.5% glucose), and serialized PD (2.5 and 4.5% glucose). Multivariate analysis (using the Weibull model) was applied to comprehensively examine survival probabilities related to the explanatory variable, while adjusting for other potential confounders. Results: Of 300 consecutive patients, 38% died over a median follow-up time of 30 months (interquartile range: 15-46 months). Multivariate analysis showed that a treatment regimen with continued higher-strength PD solution (serialized PD) resulted in a lower survival rate than when the conventional strength solution was used (adjusted hazard ratio, 2.6; 95% confidence interval, 1.6 to 4.6, p<0.01). Five interrelated risk factors (age, length of time on PD, hemoglobin levels, albumin levels, and oliguria) were significant predictors contributing to the outcome. Conclusions: Frequent exposure to high levels of glucose PD solution significantly contributed to a 2-fold higher rate of death, especially when hypertonic glucose was prescribed continuously.
Abstract
Objectives: The main purpose of this study was to quantify the risk of mortality linked to various regimens of hypertonic peritoneal dialysis (PD) solution. Methods: A retrospective cohort study of patients using home-based PD was carried out. The prescribed regimen of glucose-based PD solution for all patients, determined on the basis of their individual conditions, was extracted from their medical chart records. The primary outcome was death. The treatment regimens were categorized into 3 groups according to the type of PD solution used: original PD (1.5% glucose), shuffle PD (1.5 and 2.5% glucose), and serialized PD (2.5 and 4.5% glucose). Multivariate analysis (using the Weibull model) was applied to comprehensively examine survival probabilities related to the explanatory variable, while adjusting for other potential confounders. Results: Of 300 consecutive patients, 38% died over a median follow-up time of 30 months (interquartile range: 15-46 months). Multivariate analysis showed that a treatment regimen with continued higher-strength PD solution (serialized PD) resulted in a lower survival rate than when the conventional strength solution was used (adjusted hazard ratio, 2.6; 95% confidence interval, 1.6 to 4.6, p<0.01). Five interrelated risk factors (age, length of time on PD, hemoglobin levels, albumin levels, and oliguria) were significant predictors contributing to the outcome. Conclusions: Frequent exposure to high levels of glucose PD solution significantly contributed to a 2-fold higher rate of death, especially when hypertonic glucose was prescribed continuously.
참고문헌 (36)
- Kendrick J, "Strategies for improving long-term survival in peritoneal dialysis patients", Clin J Am Soc Nephrol, 5(6), pp.1123~1131 (2010)[DOI]
- Mateijsen MA, "Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis", Perit Dial Int, 19(6), pp.517~525 (1999)
- Teixeira JP, "Peritoneal dialysis: update on patient survival", Clin Nephrol, 83(1), pp.1~10 (2015)
- Al-Hwiesh AK, "Changes in peritoneal membrane with different peritoneal dialysis solutions: is there a difference?", Hong Kong J Nephrol, 19, pp.7~18 (2016)[DOI]
- Wen Y, "High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients", Perit Dial Int, 35(1), pp.70~77 (2015)[DOI]
- Kadota A, "Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000", Diabetes Care, 30(6), pp.1533~1538 (2007)[DOI]
- Mistry CD, "Optimal use of glucose polymer (icodextrin) in peritoneal dialysis", Perit Dial Int, 16(Suppl 1), pp.S104~S108 (1996)
- Freida P, "The contribution of combined crystalloid and colloid osmosis to fluid and sodium management in peritoneal dialysis", Kidney Int, 73(Suppl 108), pp.S102~S111 (2008)[DOI]
- Bonomini M, "L-carnitine is an osmotic agent suitable for peritoneal dialysis", Kidney Int, 80(6), pp.645~654 (2011)[DOI]
- Cho Y, "Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials", Nephrol Dial Transplant, 28(7), pp.1899~1907 (2013)[DOI]
- Li PK, "ISPD peritonitis recommendations: 2016 update on prevention and treatment", Perit Dial Int, 36(5), pp.481~508 (2016)[DOI]
- Oei E, "Peritoneal dialysis adequacy in elderly patients", Perit Dial Int, 35(6), pp.635~639 (2015)[DOI]
- Rocco M, "Peritoneal dialysis adequacy and risk of death", Kidney Int, 58(1), pp.446~457 (2000)[DOI]
- Jansen MA, "Predictors of survival in anuric peritoneal dialysis patients", Kidney Int, 68(3), pp.1199~1205 (2005)[DOI]
- Munoz de Bustillo E, "Impact of peritonitis on long-term survival of peritoneal dialysis patients", Nefrologia, 31(6), pp.723~732 (2011)
- Tong J, "Mortality and associated risk factors in dialysis patients with cardiovascular disease", Kidney Blood Press Res, 41(4), pp.479~487 (2016)[DOI]
- Wu HY, "Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis", Am J Nephrol, 28(5), pp.765~771 (2008)[DOI]
- Schoenfeld DA, "Sample-size formula for the proportional-hazards regression model", Biometrics, 39(2), pp.499~503 (1983)[DOI]
- Schemper M, "A note on quantifying follow-up in studies of failure time", Control Clin Trials, 17(4), pp.343~346 (1996)[DOI]
- Avram MM, "Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin: management of comorbidities in kidney disease in the 21st century: anemia and bone disease", Kidney Int, 64(Suppl 87), pp.S6~S11 (2003)[DOI]
- Krediet RT, "Pathophysiology of peritoneal membrane failure", Perit Dial Int, 20(Suppl 4), pp.S22~S42 (2000)
- Davies SJ, "Determinants of peritoneal membrane function over time", Semin Nephrol, 31(2), pp.172~182 (2011)[DOI]
- Hassan K, "The impact of the peritoneal glucose load index on hydration status and inflammation in peritoneal dialysis patients", J Int Med Res, 43(1), pp.42~53 (2015)[DOI]
- Holmes CJ, "Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution", J Diabetes Sci Technol, 3(6), pp.1472~1480 (2009)[DOI]
- Simon F, "Human peritoneal mesothelial cell death induced by high-glucose hypertonic solution involves Ca2+ and Na+ ions and oxidative stress with the participation of PKC", NOX2 and PI3K, Front Physiol, pp.2017, 8[DOI]
- Kang DH, "High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation", Perit Dial Int, 19(3), pp.221~230 (1999)
- Krediet RT, "Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?", NDT Plus, 1(Suppl 4), pp.iv56~iv62 (2008)
- Lv ZD, "TGF-<TEX>${\beta}1$<", TEX> induces peritoneal fibrosis by activating the Smad2 pathway in mesothelial cells and promotes peritoneal carcinomatosis, 2012, pp.29(3), 373~379
- Baroni G, "Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis", Mediators Inflamm, 2012, pp.912595~ (2012)
- Selby NM, "The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids", Nephrol Dial Transplant, 22(3), pp.870~879 (2007)[DOI]
- Rumpsfeld M, "Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations", J Am Soc Nephrol, 17(1), pp.271~278 (2006)
- Krediet RT, "Cardiovascular risk in the peritoneal dialysis patient", Nat Rev Nephrol, 6(8), pp.451~460 (2010)[DOI]
- Li PK, "The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients", Perit Dial Int, 25(Suppl 3), pp.S80~S83 (2005)
- Korbet S, "Principles and practice of dialysis", pp.185~206 (1998), Williams and Wilkins
- Davies SJ, "Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis", J Am Soc Nephrol, 12(5), pp.1046~1051 (2001)
- Holmes CJ, "Strategies to reduce glucose exposure in peritoneal dialysis patients", Perit Dial Int, 20(Suppl 2), pp.S37~S41 (2000)